Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial

Journal of the American College of Cardiology

Volumn 51, Issue 7, 2008, Pages 724-730

  Miller, Michael ^a   Cannon, Christopher P ^b   Murphy, Sabina A ^b   Qin, Jie ^b   Ray, Kausik K ^c   Braunwald, Eugene ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; GATIFLOXACIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DEATH; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UNIVARIATE ANALYSIS;

ACUTE CORONARY SYNDROME; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; PROPORTIONAL HAZARDS MODELS; PYRROLES; RECURRENCE; RISK ASSESSMENT; TRIGLYCERIDES;

EID: 38949171001     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.10.038     Document Type: Article

References (47)

1. LaRosa J.C. Understanding risk in hypercholesterolemia. Clin Cardiol 26 Suppl 1 (2003) 3-6
2. Baigent C., Keech A., Kearney P.M., et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
3. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282 (1999) 2340-2346
4. Miller M. Current perspectives on the management of hypertriglyceridemia. Am Heart J 140 (2000) 232-240
5. Criqui M.H., Heiss G., Cohn R., et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 328 (1993) 1220-1225
6. Sarwar N., Danesh J., Eiriksdottir G., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115 (2007) 450-458
7. Manninen V., Tenkanen L., Koskinen P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 85 (1992) 37-45
8. Cannon C.P., McCabe C.H., Belder R., Breen J., and Braunwald E. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 89 (2002) 860-861
9. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
10. Ray K.K., Bach R.G., Cannon C.P., et al. Benefits of achieving the NCEP optional LDL cholesterol goal among elderly patients with ACS. Eur Heart J 27 (2006) 2310-2316
11. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
12. Ray K.K., Cannon C.P., McCabe C.H., et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46 (2005) 1405-1410
13. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III Final Report) (2002), National Institutes of Health, Bethesda, MD NIH Publication No. 02-5215
14. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
15. Miller M., Seidler A., Moalemi A., and Pearson T.A. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 31 (1998) 1252-1257
16. Ridker P.M., Cannon C.P., Morrow D., et al., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
17. He Y., Lam T.H., Li L.S., Li L.S., He S.F., and Liang B.Q. Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China. Ann Epidemiol 14 (2004) 1-7
18. Assmann G. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. Am J Cardiol 87 (2001) 2B-7B
19. Giugliano R.P., and Braunwald E. The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 48 (2006) 386-395
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
21. Yu K.C., and Cooper A.D. Postprandial lipoproteins and atherosclerosis. Front Biosci 6 (2001) D332-D354
22. Greene D.J., Skeggs J.W., and Morton R.E. Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J Biol Chem 276 (2001) 4804-4811
23. Skeggs J.W., and Morton R.E. LDL and HDL enriched in triglyceride promote abnormal cholesterol transport. J Lipid Res 43 (2002) 1264-1274
24. Austin M.A., King M.C., Vranizan K.M., and Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82 (1990) 495-506
25. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
26. Imke C., Rodriguez B.L., Grove J.S., et al. Are remnant-like particles independent predictors of coronary heart disease incidence?. The Honolulu Heart Study. Arterioscler Thromb Vasc Biol 25 (2005) 1718-1722
27. Schaefer E.J. Familial lipoprotein disorders and premature coronary artery disease. Med Clin North Am 78 (1994) 21-39
28. Sacks F.M., and Katan M. Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. Am J Med 113 Suppl 9B (2002) 13S-24S
29. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded end point analysis. Lancet 369 (2007) 1090-1098
30. Harris W.S., and Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides?. Curr Opin Lipidol 17 (2006) 387-393
31. Brown B.G., and Boden W. AIM-HIGH Clinical Study. http://accelerator.axioresearch.com/aim-high Accessed December 31, 2007
32. ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 99 (2007) 21i-33i
33. Ballantyne C.M., Herd J.A., Ferlic L.L., et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 99 (1999) 736-743
34. Ballantyne C.M., and Rangaraj G.R. The evolving role of high-density lipoprotein in reducing cardiovascular risk. Prev Cardiol 4 (2001) 65-72
35. Parhofer K.G., Barrett P.H., and Schwandt P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. J Clin Endocrinol Metab 85 (2000) 4224-4230
36. Rezaie-Majd A., Prager G.W., Bucek R.A., et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 23 (2003) 397-403
37. Calabresi L., Gomaraschi M., Villa B., Omoboni L., et al. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 22 (2002) 656-661
38. Ridker P.M., Morrow D.A., Rose L.M., Rifai N., Cannon C.P., and Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 45 (2005) 1644-1648
39. Ray K.K., Cannon C.P., Cairns R., et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46 (2005) 1417-1424
40. Simpson H.C., Mann J.I., Meade T.W., Chakrabarti R., Stirling Y., and Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1 (1983) 786-790
41. Chan P., Huang T.Y., Shieh S.M., Lin T.S., and Tsai C.W. Thrombophilia in patients with hypertriglyceridemia. J Thromb Thrombolysis 4 (1997) 425-429
42. Ray K.K., and Cannon C.P. Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis 18 (2004) 89-101
43. Linton M.F., and Fazio S. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep 6 (2004) 148-157
44. Brown B.G. Can niacin slow the development of atherosclerosis in coronary artery disease patients already taking statins?. Nat Clin Pract Cardiovasc Med 2 (2005) 234-235
45. Giannini S., Serio M., and Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 27 (2004) 982-991
46. Gelfand E.V., and Cannon C.P. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 47 (2006) 1919-1926
47. Gaziano J.M., Hennekens C.H., O'Donnell C.J., Breslow J.L., and Buring J.E. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 96 (1997) 2520-2525